Citations

Showing 10 of 108119 citations.

Chronic HIV Infection and Aging: Application of a Geroscience-Guided Approach
Masters, Mary C., Landay, Alan L., Robbins, Paul D., Tchkonia, Tamar, Kirkland, James L., Kuchel, George A., Niedernhofer, Laura J., Palella, Frank J., Niedernhofer, Laura J. , Niedernhofer, Laura J , Masters, Mary Clare , Landay, Alan L., Robbins, Paul D., Tchkonia, Tamar, Kirkland, James L., Kuchel, George A., Palella, Frank J.

Mayo Clinic

JAIDS Journal of Acquired Immune Deficiency Syndromes | January 11, 2022 | Volume: 89 | Issue: S1 | Pages: S34-S46

10.1097/qai.0000000000002858 | PMID 35015744 Get It

Abstract: The ability of virally suppressive antiretroviral therapy use to extend the life span of people with HIV (PWH) implies that the age of PWH will also increase. Among PWH, extended survival comes at a cost of earlier onset and increased rates of aging-associated comorbidities and geriatric syndromes, with persistent inflammation and immune dysregulation consequent to chronic HIV infection and to antiretroviral therapy use contributing to an overall decrease in health span. The geroscience hypothesis proposes that the root causes of most aging-related chronic diseases and conditions is the aging process itself. Hence, therapeutically targeting fundamental aging processes could have a greater impact on alleviating or delaying aging-associated comorbidities than addressing each disease individually. Extending the geroscience hypothesis to PWH, we speculate that targeting basic mechanisms of aging will improve overall health with age. Clinical features and pathophysiologic mechanisms of chronic diseases in PWH qualitatively resemble those seen in older adults without HIV. Therefore, drugs that target any of the pillars of aging, including metformin, rapamycin, and nicotinamide adenine dinucleotide precursors, may also slow the rate of onset of age-associated comorbidities and geriatric syndromes in PWH. Drugs that selectively induce apoptosis of senescent cells, termed senolytics, may also improve health span among PWH. Preliminary evidence suggests that senescent cell burden is increased in PWH, implying that senescent cells are an excellent therapeutic target for extending health span. Recently initiated clinical trials evaluating senolytics in age-related diseases offer insights into the design and potential implementation of similar trials for PWH.
Impact of COVID-19 on Hematology-Oncology Fellowship Programs: A Quantitative and Qualitative Survey Assessment of Fellowship Program Directors
Velázquez, Ana I. , Durani, Urshila , Weeks, Lachelle D. , Major, Ajay , Reynolds, Robby , Kumbamu, Ashok , Das, Devika , Murphy, Martina, Henry, Elizabeth , Lee, Alfred Ian , Marshall, Ariela L. , Lee, Alfred I , Marshall, Ariela , Weeks, Lachelle Dawn , Major, Ajay , Henry, Elizabeth , Velazquez, Ana I , Durani, Urshila , Reynolds, Robby

Mayo Clinic

JCO Oncology Practice | January 11, 2022 | Volume: 18 | Issue: 4 | Pages: e551-e563

10.1200/op.21.00634 | PMID 35015586 Get It

PURPOSE: The COVID-19 pandemic led to unprecedented challenges in medical training, and we sought to assess the specific impact of COVID-19 on hematology-oncology (HO) fellowship programs. METHODS: We conducted a cross-sectional anonymous online survey of 103 HO program directors (PDs) in conjunction with the American Society of Hematology (ASH) and ASCO. We sought to assess the specific impact of COVID-19 on HO fellowship programs' clinical, educational, and research activities, evaluate perceptions regarding PD and trainee emotional and mental health, and identify ways to support programs. Data were analyzed using descriptive statistics, parametric and nonparametric tests, and multivariable logistic regression models. Responses to open-ended questions were analyzed with thematic analysis. RESULTS: Significant changes to fellowship activities included transitioning fellow training from outpatient clinics to telehealth (77.7%), shifting to virtual education (94.2%), and moving to remote research work (63.1%). A minority (21.4%) of PDs reported that their fellows were redeployed to cover non-HO services. Most PDs (54.4%) believed COVID-19 had a slight negative impact on fellowship training. PD self-reported burnout increased significantly from 15.5% prepandemic to 44.7% during the pandemic, and most PDs witnessed minor signs of fellow burnout (52.4%). Common PD concerns included inadequate supervision for telehealth activities, reduced opportunities for fellow advancement and promotion, lack of professional development activities, limited research operations and funding, program financial constraints, and virtual recruitment. CONCLUSION: We encourage institutions and national societies to allocate resources and develop programs that can support fellowships and mitigate the potential negative effects of COVID-19 on trainee and PD career development.
Genetic variants associated with acamprosate treatment response in alcohol use disorder patients: A multiple omics study
Ho, Ming‐Fen , Zhang, Cheng, Wei, Lixuan, Zhang, Lingxin, Moon, Irene, Geske, Jennifer R., Skime, Michelle K., Choi, Doo‐Sup, Biernacka, Joanna M., Oesterle, Tyler S., Frye, Mark A., Seppala, Marvin D., Karpyak, Victor M., Li, Hu, Weinshilboum, Richard M., Geske, Jennifer R. , Oesterle, Tyler , Wei, Lixuan , Oesterle, Tyler S , Geske, Jennifer , Ho, Ming-Fen , Zhang, Cheng, Wei, Lixuan, Zhang, Lingxin, Moon, Irene, Skime, Michelle K., Choi, Doo‐Sup, Biernacka, Joanna M., Frye, Mark A., Seppala, Marvin D., Karpyak, Victor M., Li, Hu, Weinshilboum, Richard M.

Mayo Clinic

British Journal of Pharmacology | January 11, 2022 | Volume: 179 | Issue: 13 | Pages: 3330-3345

10.1111/bph.15795 | PMID 35016259 Get It

Background and Purpose Acamprosate is an anti‐craving drug used for the pharmacotherapy of alcohol use disorder (AUD). However, only some patients achieve optimal therapeutic outcomes. This study was designed to explore differences in metabolomic profiles between patients who maintained sobriety and those who relapsed, to determine whether those differences provide insight into variation in acamprosate treatment response phenotypes. Experimental Approach We previously conducted an acamprosate trial involving 442 AUD patients, and 267 of these subjects presented themselves for a 3‐month follow‐up. The primary outcome was abstinence. Clinical information, genomic data and metabolomics data were collected. Baseline plasma samples were assayed using targeted metabolomics. Key Results Baseline plasma arginine, threonine, α‐aminoadipic acid and ethanolamine concentrations were associated with acamprosate treatment outcomes and baseline craving intensity, a measure that has been associated with acamprosate treatment response. We next applied a pharmacometabolomics‐informed genome‐wide association study (GWAS) strategy to identify genetic variants that might contribute to variations in plasma metabolomic profiles that were associated with craving and/or acamprosate treatment outcome. Gene expression data for induced pluripotent stem cell‐derived forebrain astrocytes showed that a series of genes identified during the metabolomics‐informed GWAS were ethanol responsive. Furthermore, a large number of those genes could be regulated by acamprosate. Finally, we identified a series of single nucleotide polymorphisms that were associated with acamprosate treatment outcomes. Conclusion and Implications These results serve as an important step towards advancing our understanding of disease pathophysiology and drug action responsible for variation in acamprosate response and alcohol craving in AUD patients.
Multicentric Castleman disease: A single center experience of treatment with a focus on autologous stem cell transplantation
Abdallah, Nadine , Habermann, Thomas M. , Gertz, Morie A. , Lacy, Martha Q. , Rajkumar, S. Vincent , Dingli, David , Hayman, Suzanne R. , Kumar, Shaji , Kourelis, Taxiarchis , Warsame, Rahma , Kapoor, Prashant , Hwa, Yi L. , Fonder, Amie , Hobbs, Miriam, Lin, Yi , Binder, Moritz , Siddiqui, Mustaqeem , Kyle, Robert A. , Abdallah, Nadine H , Habermann, Thomas , Gertz, Morie A , Rajkumar, S Vincent , Kumar, Shaji K , Kourelis, Taxiarchis , Warsame, Rahma , Muchtar, E , Hwa, Yi L , Fonder, Amie L, Leung, Nelson , Binder, Moritz , Witzig, T.E. , Dispenzieri, Angela , Siddiqui, Mustaqeem A , Dingli, David , Lin, Yi , Buadi, Francis K. , Go, Ronald S. , Muchtar, Eli , Leung, Nelson , Witzig, Thomas E. , Dispenzieri, Angela

Mayo Clinic

American Journal of Hematology | January 11, 2022 | Volume: 97 | Issue: 4 | Pages: 401-410

10.1002/ajh.26466 | PMID 35015310 Get It

AbstractCastleman disease (CD) is a rare lymphoproliferative disease characterized by diverse clinical and pathologic features. Due to its rarity, there are limited studies comparing currently available therapies. The role of autologous stem cell transplantation (ASCT) in CD has not yet been established. In this paper, we describe the clinical characteristics, treatment choices, and outcomes in 34 Mayo Clinic patients diagnosed with multicentric CD from July 1, 2003 to April 30, 2018. Eighteen patients (53%) also met the criteria for POEMS, including 14 with the osteosclerotic variant. The first‐line treatments included: steroid monotherapy (4), cytotoxic chemotherapy (6), rituximab alone (8) or with chemotherapy (2), anti‐IL6 treatment (3), and ASCT (10). The median follow‐up was 4.8 (range: 0.1–15.2) years. The 5‐ and 10‐year overall survival rates were 84% and 71%, respectively. Sixteen patients received high‐dose chemotherapy followed by ASCT during their disease course. Among those, 14 had multicentric CD associated with POEMS. There were no transplant‐related deaths. All patients had at least a partial response to ASCT, most of whom achieved a complete response. The favorable outcomes seen with ASCT in this cohort suggest that transplantation may have a role in multicentric CD, particularly for patients with multicentric CD associated with POEMS.
Midostaurin therapy for indolent and smoldering systemic mastocytosis: Retrospective review of Mayo Clinic experience
Farrukh, Faiqa, Gangat, Naseema , Shah, Meera , Litzow, Mark R. , Elliott, Michelle A. , Begna, Kebede H. , Hook, Christopher C., Tefferi, Ayalew , Pardanani, Animesh , Shah, Mithun V , Begna, Kebede , Farrukh, Faiqa, Gangat, Naseema , Litzow, Mark R. , Elliott, Michelle , Hook, Christopher C., Tefferi, Ayalew , Pardanani, Animesh

Mayo Clinic

American Journal of Hematology | January 11, 2022 | Volume: 97 | Issue: 4 | Pages: No page available

10.1002/ajh.26464 | PMID 35015315 Get It

Incidental Colonic Ganglioneuroma on Surveillance Colonoscopy
Agarwal, Siddharth , Iyer, Prasad G. , Wang, Yaohong, Leggett, Cadman L. , Agarwal, Siddharth , Wang, Yaohong

Mayo Clinic

ACG Case Reports Journal | January 11, 2022 | Volume: 9 | Issue: 1 | Pages: e00727

10.14309/crj.0000000000000727 | PMID 35036457 Get It

Lessons Learned from Clinical and Translational Science Faculty and Student Survey as COVID-19 Pandemic Continues to Shift Education Online
Forkner, Katherine A. , Wissman, Adam W., Jimison, Ryan C. , Nelson, Kristina B. , Wuertz, Ryan E. , Silvano, Carmen J., Frazee, Erin N. , Passow, Jeanette E. Eckel, Eckel Passow, Jeanette E, Enders, Felicity T, Enders, Felicity , Staff, Nathan P.

Mayo Clinic

Journal of Medical Education and Curricular Development | January 11, 2022 | Volume: 9 | Issue: No issue available | Pages: No page available

10.1177/23821205211073253 | PMID 35036569 Get It

Introduction As the pandemic continues with new variants emerging, faculty and students require support with education's rapid shift to the virtual space. The Mayo Clinic Center for Clinical and Translational Science curriculum team works closely with faculty to support a smooth transition to offering graduate courses in a virtual learning environment. The aim of the present project was to explore faculty and student perceptions of these remote learning strategies to gain an understanding of the innovations required to improve future educational offerings. Methods All faculty and learners involved in nine Clinical and Translational Science courses in spring 2020 were invited to participate in a web-based questionnaire. Quantitative analysis was performed on closed-ended items, including 5-point Likert-scale questions used to assess the range of views. Qualitative free-text responses were independently analyzed for repetitive themes and summarized. Additionally, comparisons of faculty and course evaluations and student grade point averages (GPAs) from the in-person courses and their subsequent virtual course offerings were considered. Results Survey results indicated several positive impacts with moving courses into the virtual environment, including increased accessibility as well as more student-centered education. Learners joining from sites outside of the originating campus were especially grateful for the virtual classroom because they felt newly integrated within classes. Faculty and course evaluations, as well as student GPAs, remained consistent. Conclusion New COVID-19 variants continue to shift education online, and innovative ideas are required to further improve future virtual course offerings. Increased engagement is warranted, both from faculty to incorporate activities designed specifically for a virtual classroom, and from students to increase participation by activating their microphones and webcams. Greater opportunities for global involvement and connectedness arise. Finally, this project advocates for adequate eLearning staffing to support quality online education as the need for pedagogical and technical provision continues.
Interorgan crosstalk in pancreatic islet function and pathology
Evans, Ronald M. , Wei, Zong , Wei, Zong , Evans, Ronald M

Mayo Clinic

FEBS Letters | January 11, 2022 | Volume: 596 | Issue: 5 | Pages: 607-619

10.1002/1873-3468.14282 | PMID 35014695 Get It

Pancreatic β cells secrete insulin in response to glucose, a process that is regulated at multiple levels, including a network of input signals from other organ systems. Impaired islet function contributes to the pathogenesis of type 2 diabetes mellitus (T2DM), and targeting inter‐organ communications, such as GLP‐1 signalling, to enhance β‐cell function has been proven to be a successful therapeutic strategy in the last decade. In this review, we will discuss recent advances in inter‐organ communication from the metabolic, immune and neural system to pancreatic islets, their biological implication in normal pancreas endocrine function and their role in the (mal)adaptive responses of islet to nutrition‐induced stress.
Abstract PO-197: Combined effect of a prostate cancer polygenic risk score and germline pathogenic variants in DNA damage repair genes on prostate cancer risk in men of African ancestry
Matejcic, Marco , Patel, Yesha , Lilyquist, Jenna , Xia, Lucy , Sheng, Xin , Lubmawa, Alexander, Watya, Stephen , Conti, David V. , Haiman, Christopher A. , Conti, David V , Hughley, Raymond W. , Darst, Burcu F. , Hart, Steven N. , Polley, Eric C. , Ingles, Sue A. , Wilkens, Lynne R. , Marchand, Loı̈c Le , Couch, Fergus J.

Mayo Clinic

Cancer Epidemiology, Biomarkers & Prevention | January 11, 2022 | Volume: 31 | Issue: 1_Supplement | Pages: PO-197-PO-197

10.1158/1538-7755.disp21-po-197 Get It

Abstract Introduction: Prostate Cancer (PCa) risk is influenced by both rare germline pathogenic variants (GPVs) in DNA damage repair genes and common variants as measured by polygenic risk scores (PRS) however, the combined effect of GPVs and PRS on PCa risk in men of African ancestry has not been investigated. Methods: We examined the combined effect of rare GPVs and PRS on PCa risk in 1,795 PCa cases and 1,424 controls of African ancestry men from the Multiethnic Cohort, the Los Angeles Study of Aggressive Prostate Cancer, and the Uganda Prostate Cancer Study. GPVs in 19 DNA genes were defined as clinically validated missense variants and variants that alter the protein sequence. The PRS was constructed as a weighted sum of 267 established PCa risk variants. The combined effect of the PRS and GPV status on PCa risk was evaluated using logistic regression models adjusting for age, study, and the first 10 principal components of ancestry to account for population stratification. Results: We identified 91 GPVs carried by 31 controls and 68 cases. Among GPV non-carriers, compared to those with average PRS (33.3-66.7%), odds ratios for PCa ranged from 0.56 (95% CI=0.45-0.70; P=1.2E-7) in low PRS men (0-33.3%) to 3.04 (95% CI=2.54-3.63; P=5.6E-35) in high PRS men (66.7-100%). Among GPV carriers, odds ratios for PCa ranged from 2.09 (95% CI=0.85-5.12; P=0.11) in low PRS men to 5.03 (95% CI=2.37-10.66; P=2.5E-5) in high PRS men, compared to GPV non-carriers with average PRS. Next, we restricted GPVs to ATM, BRCA2, PALB2, and NBN[BD2] (n=51 variants carried by 8 controls and 44 cases), which we previously reported as being the genes most strongly associated with advanced PCa in this population and study sample. Among GPV non-carriers, odds ratios for PCa ranged from 0.56 (95% CI=0.46-0.71; P=2.7E-7) in low PRS men to 5.03 (95% CI=0.85-5.12; P=0.11) in high PRS men, while among GPV carriers, odd ratios for PCa ranged from 2.08 (95% CI=0.58-7.49; P=0.26) in low PRS men to 18.06 (95% CI=4.24-76.84; P=9.0E-5) in high PRS men, compared to average PRS GPV non-carriers. When comparing aggressive cases to controls, considering the top four genes, GPV non-carrier odds ratios for PCa ranged from 0.52 (95% CI=0.40-0.70; P=6.2E-6) in low PRS men to 3.16 (95% CI=2.56-3.91; P=1.6E-26) in high PRS men, while among GPV carriers, odd ratios for PCa ranged from 2.97 (95% CI=073-12.16; P=0.13) in low PRS men to 23.58 (95% CI=5.39-103.20; P=2.7E-5) in high PRS men, compared to average PRS GPV non-carriers. Conclusion: We found that PCa risk in African ancestry men carrying GPVs in DNA damage repair and cancer predisposition genes, particularly ATM, BRCA2, PALB2, and NBN, varied depending on an individual's PRS. This implies that to comprehensively assess genetic risk of PCa, it is important to consider both rare and common variants. These findings could have implications for risk stratification in this high-risk population and emphasize the need for larger genetic studies of PCa in African ancestry men to identify and characterize genetic risk factors in this population. Citation Format: Raymond W. Hughley, Burcu F. Darst, Marco Matejcic, Yesha Patel, Jenna Lilyquist, Steven N. Hart, Eric C. Polley, Lucy Xia, Xin Sheng, Alexander Lubmawa, Sue A. Ingles, Lynne Wilkens, Loïc L. Marchand, Stephen Watya, Fergus J. Couch, David V. Conti, Christopher A. Haiman. Combined effect of a prostate cancer polygenic risk score and germline pathogenic variants in DNA damage repair genes on prostate cancer risk in men of African ancestry [abstract]. In: Proceedings of the AACR Virtual Conference: 14th AACR Conference on the Science of Cancer Health Disparities in Racial/Ethnic Minorities and the Medically Underserved; 2021 Oct 6-8. Philadelphia (PA): AACR; Cancer Epidemiol Biomarkers Prev 2022;31(1 Suppl):Abstract nr PO-197.
Abstract PO-104: Disparity in race and age reporting in landmark cancer clinical trials: Underrepresentation of the traditionally underserved U.S. population
Baksh, Mizba , Ailawadhi, Meghna, Samreen, Ayesha , Sher, Taimur , Paulus, Aneel , Chanan‐Khan, Asher , Paulus, Aneel , Jayakrishnan, Thejus , Aulakh, Sonikpreet , Nguyen, Kianna M. , Parrondo, Ricardo D , Roy, Vivek , Manochakian, Rami , Ailawadhi, Sikander

Mayo Clinic

Cancer Epidemiology, Biomarkers & Prevention | January 11, 2022 | Volume: 31 | Issue: 1_Supplement | Pages: PO-104-PO-104

10.1158/1538-7755.disp21-po-104 Get It

Abstract Background: Concern exists that the clinical trial populations differ from respective cancer populations in terms of their age distribution affecting the generalizability of the results, especially the underrepresented minorities. We hypothesized that the clinical trials that do not report race are likely to suffer from a higher degree of age disparity as well and the issue should be addressed in conjunction with each other. Methods: Food and Drug Administration (FDA) drug approvals from 7/2007-6/2019 were reviewed to identify oncology approvals, and trials with age details were selected. The primary outcome was the weighted mean difference in age between the clinical trial population and realworld population for various cancers. The secondary outcomes were the prevalence of race reporting and association of age and race reporting with each other. Group comparisons for proportions were performed using the χ2 test while continuous variables were compared using multiple analysis of variance (MANOVA) test or students t-test as appropriate. P values < .05 were considered significant. Results: Of the 261 trials, the race was reported in 223 (85.4%) of the trials while 38 trials (14.6%) had no mention of race. Race reporting improved minimally over time – 29 (85.3%) in 2007-2010 vs. 49 (80.3%) in 2011-2014 vs. 145 (85.4%) during 2015-2019 (p-value=0.41). No significant association between type of cancer and race reporting was noted – 147 (86.5%) of solid cancer trials vs. 76 (83.5%) of hematological cancer trials reported race (p-value=0.52). Age discrepancy between the clinical trial population and the real-world population was present for several cancer types. The discrepancy was higher for studies that did not report race, mean difference - 8.8 years 4 (95% CI -12.6 to -5.0 years) vs. studies that did report the race, mean difference -5.1 years, (95% CI -6.4 to -3.7 years), p-value=0.04. Conclusion: The study demonstrates that a significant number of clinical trials leading to cancer drug approvals suffer from racial and age disparity when compared to real-world populations and that the two factors may be interrelated. We recommend continued efforts to recruit diverse populations. In the meantime, reporting these characteristics for these crucial trials should be mandated. Citation Format: Thejus Jayakrishnan, Sonikpreet Aulakh, Mizba Baksh, Kianna Nguyen, Meghna Ailawadhi, Ayesha Samreen, Ricardo Parrondo, Taimur Sher, Vivek Roy, Rami Manochakian, Aneel Paulus, Asher Chanan-Khan, Sikander Ailawadhi. Disparity in race and age reporting in landmark cancer clinical trials: Underrepresentation of the traditionally underserved U.S. population [abstract]. In: Proceedings of the AACR Virtual Conference: 14th AACR Conference on the Science of Cancer Health Disparities in Racial/Ethnic Minorities and the Medically Underserved; 2021 Oct 6-8. Philadelphia (PA): AACR; Cancer Epidemiol Biomarkers Prev 2022;31(1 Suppl):Abstract nr PO-104.